Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas

Pediatric Radiology

Volumn 42, Issue 10, 2012, Pages 1218-1222

  Karmazyn, Boaz ^a   Cohen, Mervyn D ^a   Jennings, Samuel Gregory ^a   Robertson, Kent A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; MRI; Plexiform neurofibromatosis

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW EDEMA; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FEMUR; FOLLOW UP; HUMAN; MALE; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE SCANNER; PILOT STUDY; PLEXIFORM NEUROFIBROMA; PRIORITY JOURNAL; TIBIA; WHOLE BODY MRI;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; PILOT PROJECTS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84867883342     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-012-2440-0     Document Type: Article

References (17)

1. Borthakur G, Cortes JE (2004) Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol 79:411-419
2. Siddiqui MA, Scott LJ (2007) Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 67:805-820
3. Jett K, Friedman JM (2010) Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12:1-11
4. Zoller ME, Rembeck B, Oden A et al (1997) Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125-2131
5. Evans DG, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311-314
6. Yang FC, Ingram DA, Chen S et al (2008) Nf1-dependent tumors require a microenvironment containing Nf1 and c-kit-dependent bone marrow. Cell 135:437-448
7. DemestreM, Herzberg J, Holtkamp N et al (2010) Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 98:11-19
8. McClelland CM, Harocopos GJ, Custer PL (2010) Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol 4:427-431
9. Larson JS, Bergstrom LK, Cameron JD et al (2007) Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Arch Ophthalmol 125:985-986
10. Esmaeli B, Prieto VG, Butler CE et al (2002) Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95:881-887
11. Valeyrie L, Bastuji-Garin S, Revuz J et al (2003) Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosomepositive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 48:201-206
12. Kelly K, Swords R, Mahalingam D et al (2009) Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 4:99-105
13. VanelD, Bonvalot S, Pechoux CL et al (2007) Imatinib-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. Skeletal Radiol 36:895-898
14. Tamura T, Tasaka T, Fujimoto M et al (2004) Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Haematologica 89:109-110
15. Berman E, Nicolaides M, Maki RG et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006-2013
16. Pietras K, Ostman A, Sjoquist M et al (2001) Inhibition of plateletderived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934
17. Bankier AA, Levine D, Halpern EF et al (2010) Consensus interpretation in imaging research: is there a better way? Radiology 257:14-17